Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

JNJ 95.16 -1.06 (-1.10%)
price chart
Johnson & Johnson Reaches Settlement in 845 Levaquin Cases
Nov. 1 (Bloomberg) -- Johnson & Johnson settled lawsuits with about 845 plaintiffs who claimed the drugmaker didn't properly warn of the risks of tendon damage from its antibiotic Levaquin.
J&J's Global Media Review Hits Halfway Mark
Johnson & Johnson is midway through a global review of its media planning and buying business with its decision in the North American market this week.
Johnson & Johnson Elects CEO Gorsky Chairman
Johnson & Johnson (JNJ) said it elected new CEO Alex Gorsky as chairman on Friday, replacing Bill Weldon who will step down later this year with plans to retire in the first quarter of 2013.
Weldon passes baton at Johnson & Johnson to Gorsky
Johnson & Johnson Campaign for Nursing's Future turns 10
In response to this dire scenario, The Johnson & Johnson Campaign for Nursing's Future emerged in 2002. It had a number of highly ambitious goals, including improving the nursing profession's image, recruiting new nurses and retaining RNs already in ...
Warren Buffett Buys More Wells Fargo and IBM, Sells Johnson & Johnson
In the previous article we reported that Berkshire Hathaway bought into 4 new stocks and sold 3 old ones. As pointed by readers, most of those positions are not Warren Buffett's.
Warren Buffett Buys Deere and Wabco; Sells Johnson & Johnson and P&G  ValueWalk
Buffett's Berkshire Sells Most of J&J and GE Stakes
Johnson & Johnson, Merck and Eli Lilly to rip red tape from clinical trials
Johnson & Johnson's ($JNJ) Janssen R&D unit is leading a charge to expedite the tedious process of selecting sites for clinical trial sites, with the creation of a investigator database intended to get studies up and running more efficiently.
J&J, Lilly, Merck plan clinical trial site database  Reuters
Janssen Forms “Investigator Databank” to Help Streamline Drug Trials  Xconomy
Johnson & Johnson One-Ups Tuberculosis
In an 18-0 ruling on efficacy, the FDA advisory committee voted in favor of Johnson & Johnson's bedaquiline, a drug to combat multidrug-resistant tuberculosis.
J&J says it won't enforce AIDS drug patent in Africa
LONDON Generic manufacturers are to be given a free rein to make cheap copies of Johnson & Johnson's HIV/AIDS drug Prezista for sale in Africa and other poor countries.
J&J opens HIV fighter Prezista to copycats in poor countries  FiercePharma
Johnson & Johnson Is Undervalued — Here's Why
The reason behind this perceived overvaluation of Johnson & Johnson is the fact that there were a few one-time charges against earnings, which decreased them.
Buy Johnson & Johnson For Rock Solid Dividends - No Capital Appreciation Expected
Johnson & Johnson (NYSE:JNJ) operates under three segments: Pharmaceutical (eighth largest in the world), Medical Devices and Diagnostic (the largest in the world) and Consumer (6th largest in the world).